SCHEMBL8208262

SCHEMBL8208262

CC(C)NC(=O)c1cccc(C(=O)NCC2CCN(c3cccc(S(C)(=O)=O)c3)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.47
GPR119 Q8TDV5 1/20 0.46
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NR1H3 Q13133 8/20 0.42
NR1H2 P55055 8/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PTGDR Q13258 1/20 0.41
DRD2 P14416 2/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8208875 0.91 LMNA (0.48) GPR119LMNASMN1; SMN2HPGDALDH1A1
SCHEMBL8208874 0.87 PDGFRB (0.43) LMNASMN1; SMN2HPGDALDH1A1POLB
SCHEMBL12853613 0.83 USP30 (0.51) CHRM4DRD2
SCHEMBL8201048 0.79 USP30 (0.47) CHRM4LMNASMN1; SMN2HPGDALDH1A1
SCHEMBL17011998 0.76 LMNA (0.46) GPR119LMNASMN1; SMN2HPGDALDH1A1
SCHEMBL8205788 0.74 ADRB2 (0.43) ALDH1A1POLBHSD17B10KDM4E
SCHEMBL8206262 0.74 KDM4E (0.64) GPR119MEN1KMT2AKDM4E
SCHEMBL8213923 0.71 ALDH1A1 (0.49) ALDH1A1HSD17B10NR1H2
SCHEMBL12853363 0.71 MAPK8 (0.52) ALDH1A1HSD17B10NR1H2
SCHEMBL8198448 0.70 KDM4E (0.56) GPR119MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 CHRM4 2738/4885GPR119 367/4885LMNA 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.